Morgan Stanley’s La Jolla Pharmaceutical Company LJPC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-43,307
| Closed | -$138K | – | 8238 |
|
|
2022
Q2 | $138K | Sell |
43,307
-758
| -2% | -$2.95K | ﹤0.01% | 6101 |
|
|
2022
Q1 | $188K | Sell |
44,065
-23,611
| -35% | -$103K | ﹤0.01% | 5961 |
|
|
2021
Q4 | $315K | Sell |
67,676
-38,818
| -36% | -$162K | ﹤0.01% | 5815 |
|
|
2021
Q3 | $425K | Sell |
106,494
-153,259
| -59% | -$608K | ﹤0.01% | 5595 |
|
|
2021
Q2 | $1.11M | Sell |
259,753
-167,930
| -39% | -$719K | ﹤0.01% | 5016 |
|
|
2021
Q1 | $1.81M | Buy |
427,683
+22,290
| +5% | +$123K | ﹤0.01% | 4332 |
|
|
2020
Q4 | $1.57M | Sell |
405,393
-489,292
| -55% | -$2.09M | ﹤0.01% | 4357 |
|
|
2020
Q3 | $3.6M | Buy |
894,685
+227,074
| +34% | +$941K | ﹤0.01% | 3043 |
|
|
2020
Q2 | $2.84M | Buy |
667,611
+29,491
| +5% | +$180K | ﹤0.01% | 3252 |
|
|
2020
Q1 | $2.68M | Buy |
638,120
+256,246
| +67% | +$1.62M | ﹤0.01% | 3090 |
|
|
2019
Q4 | $1.5M | Sell |
381,874
-468,424
| -55% | -$2.77M | ﹤0.01% | 4251 |
|
|
2019
Q3 | $7.48M | Buy |
850,298
+429,436
| +102% | +$4.06M | ﹤0.01% | 2430 |
|
|
2019
Q2 | $3.89M | Buy |
420,862
+2,780
| +0.7% | +$21K | ﹤0.01% | 3177 |
|
|
2019
Q1 | $2.69M | Buy |
418,082
+358,482
| +601% | +$2.33M | ﹤0.01% | 3336 |
|
|
2018
Q4 | $563K | Buy |
59,600
+16,707
| +39% | +$251K | ﹤0.01% | 4707 |
|
|
2018
Q3 | $863K | Sell |
42,893
-14,394
| -25% | -$376K | ﹤0.01% | 4656 |
|
|
2018
Q2 | $1.67M | Buy |
57,287
+8,370
| +17% | +$258K | ﹤0.01% | 4245 |
|
|
2018
Q1 | $1.46M | Sell |
48,917
-4,321
| -8% | -$139K | ﹤0.01% | 4269 |
|
|
2017
Q4 | $1.71M | Buy |
53,238
+6,926
| +15% | +$226K | ﹤0.01% | 4152 |
|
|
2017
Q3 | $1.61M | Sell |
46,312
-27,920
| -38% | -$898K | ﹤0.01% | 4069 |
|
|
2017
Q2 | $2.21M | Buy |
74,232
+9,347
| +14% | +$268K | ﹤0.01% | 3709 |
|
|
2017
Q1 | $1.94M | Sell |
64,885
-93,342
| -59% | -$2.38M | ﹤0.01% | 3842 |
|
|
2016
Q4 | $2.77M | Buy |
158,227
+38,017
| +32% | +$729K | ﹤0.01% | 3615 |
|
|
2016
Q3 | $2.86M | Sell |
120,210
-18,451
| -13% | -$348K | ﹤0.01% | 3196 |
|
|
2016
Q2 | $2.22M | Buy |
138,661
+33,735
| +32% | +$605K | ﹤0.01% | 3341 |
|
|
2016
Q1 | $2.19M | Sell |
104,926
-56,191
| -35% | -$1M | ﹤0.01% | 3272 |
|
|
2015
Q4 | $4.35M | Sell |
161,117
-138,095
| -46% | -$3.77M | ﹤0.01% | 2798 |
|
|
2015
Q3 | $8.32M | Buy |
299,212
+173,726
| +138% | +$5.47M | ﹤0.01% | 2154 |
|
|
2015
Q2 | $3.08M | Buy |
125,486
+36,156
| +40% | +$745K | ﹤0.01% | 3227 |
|
|
2015
Q1 | $1.64M | Buy |
89,330
+14,895
| +20% | +$302K | ﹤0.01% | 3762 |
|
|
2014
Q4 | $1.37M | Buy |
74,435
+32,476
| +77% | +$385K | ﹤0.01% | 3887 |
|
|
2014
Q3 | $403K | Buy |
41,959
+39,459
| +1,578% | +$393K | ﹤0.01% | 4712 |
|
|
2014
Q2 | $23K | Sell |
2,500
-6,550
| -72% | -$59.8K | ﹤0.01% | 5997 |
|
|
2014
Q1 | $98K | Buy |
+9,050
| New | +$88.8K | ﹤0.01% | 5456 |
|
Morgan Stanley's LJPC Position: Q3 2022 in Review
Morgan Stanley sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2022, closing a stake of 43,307 shares — an estimated $138K sold.
Morgan Stanley first reported a position in LJPC in Q1 2014 and held it in 34 quarters. The position peaked at $8.32M in Q3 2015. 0 funds tracked by Wall St. Rank hold LJPC as of Q3 2022.
- Morgan Stanley reported no remaining La Jolla Pharmaceutical Company position as of Q3 2022 after selling out during the quarter.
- Morgan Stanley sold 43,307 La Jolla Pharmaceutical Company shares in Q3 2022, an estimated $138K.
- Morgan Stanley first reported a position in La Jolla Pharmaceutical Company in Q1 2014 and held it in 34 quarters.
- Morgan Stanley's La Jolla Pharmaceutical Company position peaked at $8.32M in Q3 2015.
- 0 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2022.
Based on Morgan Stanley's 13F filing for Q3 2022, filed 14 Nov 2022.